Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparison of ceftriaxone with cefoxitin in the treatment of penicillin-resistant gonococcal urethritis.

Literature DB >> 6303490

Comparison of ceftriaxone with cefoxitin in the treatment of penicillin-resistant gonococcal urethritis.

T R Zajdowicz, P L Sanches, S W Berg, S B Kerbs, R L Newquist, W O Harrison.

Abstract

Since cefoxitin has been shown to be an effective alternative to spectinomycin for the treatment of infections due to penicillinase-producing strains of Neisseria gonorrhoeae (PPNG) its efficacy was compared with that of a new cephalosporin, ceftriaxone (R013-9904). One hundred and twenty eight men with culture-confirmed gonococcal urethritis were treated with either 250 mg of ceftriaxone intramuscularly or 2 g of cefoxitin intramuscularly with oral probenecid 1 g. The incidence of penicillin-resistant strains in each group was about 60%. Ceftriaxone was completely effective in treating both penicillin-sensitive and penicillin-resistant gonococcal urethritis. No side effects were noted. Ceftriaxone thus seems to be an effective and safe alternative to either spectinomycin or cefoxitin in the treatment of penicillin-resistant gonococcal urethritis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1983 PMID： 6303490 PMCID： PMC1046170 DOI： 10.1136/sti.59.3.176

Source DB: PubMed Journal: Br J Vener Dis ISSN： 0007-134X

8 in total

1. Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae.

Authors: W A Ashford; D W Potts; H J Adams; J C English; S R Johnson; J W Biddle; C Thornsberry; H W Jaffe
Journal: Lancet Date: 1981-11-07 Impact factor: 79.321

2. Penicillinase-producing Neisseria gonorrhoeae.

Authors: W A Ashford; R G Golash; V G Hemming
Journal: Lancet Date: 1976-09-25 Impact factor: 79.321

3. Penicillinase-producing Gonococci in Liverpool.

Authors: A Percival; J Rowlands; J E Corkill; C D Alergant; O P Arya; E Rees; E H Annels
Journal: Lancet Date: 1976-12-25 Impact factor: 79.321

4. In vitro susceptibility of Haemophilus influenzae and neisseria gonorrhoeae to Ro 13-9904 in comparison with other beta-lactam antibiotics.

Authors: W S Ng; P Y Chau; K Arnold
Journal: Antimicrob Agents Chemother Date: 1981-05 Impact factor: 5.191

5. Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae.

Authors: S W Berg; M E Kilpatrick; W O Harrison; J A McCutchan
Journal: N Engl J Med Date: 1979-09-06 Impact factor: 91.245

6. Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

Authors: P Angehrn; P J Probst; R Reiner; R L Then
Journal: Antimicrob Agents Chemother Date: 1980-12 Impact factor: 5.191

7. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors: C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal: Antimicrob Agents Chemother Date: 1972-04 Impact factor: 5.191

8. Pharmacokinetics of ceftriaxone in humans.

Authors: I H Patel; S Chen; M Parsonnet; M R Hackman; M A Brooks; J Konikoff; S A Kaplan
Journal: Antimicrob Agents Chemother Date: 1981-11 Impact factor: 5.191

8 in total

13 in total

1. In-vitro susceptibility of 400 isolates of Neisseria gonorrhoeae in Vancouver, 1982-84.

Authors: W R Bowie; C E Shaw; D G Chan; H D Jones; W A Black
Journal: CMAJ Date: 1986-09-01 Impact factor: 8.262

2. Randomised observer blind comparative trial of ceftriaxone and penicillin in treating uncomplicated gonorrhoea in men and women.

Authors: C A Dixon; J B Bittiner; M Shahidullah; R C Slack; M Z Sulaiman
Journal: Genitourin Med Date: 1986-04

Review 3. Role of cephalosporins in gonorrhoea and other sexually transmitted diseases.

Authors: I Phillips
Journal: Drugs Date: 1987 Impact factor: 9.546

Review 4. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors: R N Brogden; A Ward
Journal: Drugs Date: 1988-06 Impact factor: 9.546

Comparison of ceftriaxone with cefoxitin in the treatment of penicillin-resistant gonococcal urethritis.

1. Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae.

2. Penicillinase-producing Neisseria gonorrhoeae.

3. Penicillinase-producing Gonococci in Liverpool.

4. In vitro susceptibility of Haemophilus influenzae and neisseria gonorrhoeae to Ro 13-9904 in comparison with other beta-lactam antibiotics.

5. Cefoxitin as a single-dose treatment for urethritis caused by penicillinase-producing Neisseria gonorrhoeae.

6. Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies.

7. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

8. Pharmacokinetics of ceftriaxone in humans.

1. In-vitro susceptibility of 400 isolates of Neisseria gonorrhoeae in Vancouver, 1982-84.

2. Randomised observer blind comparative trial of ceftriaxone and penicillin in treating uncomplicated gonorrhoea in men and women.

Review 3. Role of cephalosporins in gonorrhoea and other sexually transmitted diseases.

Review 4. Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

5. Cefonicid as therapy for uncomplicated gonococcal urethritis caused by penicillinase-producing Neisseria gonorrhoeae.

Review 6. Cephalosporin-probenecid drug interactions.

Review 7. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Review 8. The use of cephalosporins for gonorrhea: the impending problem of resistance.

Review 9. Beta-lactams in sexually transmitted diseases: rationale for selection and dosing regimens.

10. Treating genitourinary and pharyngeal gonorrhoea with single dose ceftriaxone.